Cyclophosphamide exposure in pediatric systemic lupus erythematosus is associated with reduced serum anti-müllerian hormone levels

Journal of Rheumatology

Volumn 40, Issue 6, 2013, Pages 1029-1031

  Isgro, Josephine ^a   Nurudeen, Sahadat K ^a   Imundo, Lisa F ^a   Sauer, Mark V ^a   Douglas, Nataki C ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; MUELLERIAN INHIBITING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL CONTRACEPTIVE AGENT; PREDNISONE;

ADOLESCENT; ADULT; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG USE; FEMALE; FEMALE INFERTILITY; GRANULOSA CELL; HORMONE BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MENARCHE; MENSTRUAL CYCLE; MUELLERIAN INHIBITING FACTOR BLOOD LEVEL; ONSET AGE; OVARY FOLLICLE; OVARY INSUFFICIENCY; PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; RISK ASSESSMENT; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ANTI-MULLERIAN HORMONE; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS; YOUNG ADULT;

EID: 84878634897     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130017     Document Type: Letter

References (10)

1. Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am 2012;59:345-64.
2. Hickman RA, Gordon C. Causes and management of infertility in systemic lupus erythematosus. Rheumatol 2011;50:1551-8.
3. Silva CA, Deen ME, Febronio MV, Oliveira SK, Terreri MT, Sacchetti SB, et al. Hormone profile in juvenile systemic lupus erythematosus with previous or current amenorrhea. Rheumatol Int 2011;31:1037-43.
4. Nelson SM, Anderson RA, Broekmans FJ, Raine-Fenning N, Fleming R, La Marca A. Anti-Mullerian hormone: clairvoyance or crystal clear? Hum Reprod 2012;27:631-6.
5. Clowse ME, Harward L, Criscione-Schreiber L, Pisetsky D, Copland S. Anti-Mullerian hormone: a better marker of ovarian damage from cyclophosphamide. Arthritis Rheum 2012;64:1305-10.
6. van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 2005;83:979-87.
7. Yu B, Douglas N, Ferin MJ, Nakhuda GS, Crew K, Lobo RA, et al. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 2010;116:2099-105.
8. Aikawa NE, Sallum AM, Pereira RM, Suzuki L, Viana VS, Bonfa E, et al. Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy. Clin Exp Rheumatol 2012;30:445-9.
9. Hagen CP, Vestergaard S, Juul A, Skakkebaek NE, Andersson AM, Main KM, et al. Low concentration of circulating antimullerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study. Fertil Steril 2012;98:1602-8.
10. Marder W, McCune WJ, Wang L, Wing JJ, Fisseha S, McConnell DS, et al. Adjunctive GnRH - a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol 2012;28:624-7.